News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GenSpera and the Statewide Clinical Trials Network of Texas to Conduct Phase II Study of G-202 in Patients With Hepatocellular Carcinoma



10/25/2012 9:55:44 AM

SAN ANTONIO, Texas--(BUSINESS WIRE)--GenSpera, Inc. (OTCBB:GNSZ) announced that its lead drug, G-202, has been selected by the Statewide Clinical Trials Network of Texas (CTNeT) for evaluation in a Phase II clinical trial in patients with hepatocellular carcinoma (HCC). CTNeT’s selection of G-202 is the result of a competitive, peer-review process to identify promising molecularly-targeted agents with likelihood of clinical benefit and rapidly move them into the Phase II setting. The clinical trial, entitled “A Phase II, Multicenter, Single-Arm Study of G-202 as Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma” is the first clinical trial launched by CTNeT, an organization founded by a grant from the Cancer Prevention and Research Institute of Texas (CPRIT) and focused on moving targeted therapies and clinical research forward at an accelerated pace.

Read at BioSpace.com


comments powered by Disqus
GenSpera
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES